Skip to content
  • For Researchers
  • For Healthcare Professionals
  • Contact Us
  • For Researchers
  • For Healthcare Professionals
  • Contact Us
  • FR
  • FR
×
Facebook-f Twitter Instagram Youtube Linkedin
Defeat Duchenne Canada
  • About Duchenne
    • Introduction
    • Duchenne Basics
      • What is Duchenne Muscular Dystrophy?
      • What Causes Duchenne Muscular Dystrophy?
        • The Role of Dystrophin
      • Genetics
        • Types of Mutations
        • Carriers
    • Diagnosis
      • Signs and Symptoms
      • Genetic and Diagnostic Testing
  • Living with Duchenne
    • Introduction
    • Duchenne Management
      • Phases of Duchenne
      • Emergency Care
      • Your Care Team
    • Canadian Neuromuscular Registry
    • Family Stories
    • Education & Support
      • Family Forums
      • Webinars
      • Canadians Talk Duchenne
      • Helpful Resources
    • Research & Clinical Trials
      • Areas of Duchenne Research
      • About Clinical Trials
        • Clinical Trial Finder Tool
      • Research We Fund
        • Our Impact in Research
  • Join the Fight
    • Introduction
    • Give a Gift
      • Personal Giving
        • Donate Now
      • Legacy & Planned Giving
      • Corporate Giving
      • Your Gift in Action
    • Fundraise
    • Volunteer
      • Volunteer Opportunities
      • Volunteer Application
  • News & Events
    • News
    • Events
  • Our Impact
    • Introduction
    • Our Mission
    • Our History
    • Our Work
    • Our Families
  • For Researchers
  • For Healthcare Professionals
  • Contact Us
    • Our Team
  • About Duchenne
    • Introduction
    • Duchenne Basics
      • What is Duchenne Muscular Dystrophy?
      • What Causes Duchenne Muscular Dystrophy?
        • The Role of Dystrophin
      • Genetics
        • Types of Mutations
        • Carriers
    • Diagnosis
      • Signs and Symptoms
      • Genetic and Diagnostic Testing
  • Living with Duchenne
    • Introduction
    • Duchenne Management
      • Phases of Duchenne
      • Emergency Care
      • Your Care Team
    • Canadian Neuromuscular Registry
    • Family Stories
    • Education & Support
      • Family Forums
      • Webinars
      • Canadians Talk Duchenne
      • Helpful Resources
    • Research & Clinical Trials
      • Areas of Duchenne Research
      • About Clinical Trials
        • Clinical Trial Finder Tool
      • Research We Fund
        • Our Impact in Research
  • Join the Fight
    • Introduction
    • Give a Gift
      • Personal Giving
        • Donate Now
      • Legacy & Planned Giving
      • Corporate Giving
      • Your Gift in Action
    • Fundraise
    • Volunteer
      • Volunteer Opportunities
      • Volunteer Application
  • News & Events
    • News
    • Events
  • Our Impact
    • Introduction
    • Our Mission
    • Our History
    • Our Work
    • Our Families
  • For Researchers
  • For Healthcare Professionals
  • Contact Us
    • Our Team
Donate Now
  • FR
  • FR
×

Capricor Therapeutics: Positive 18-Month Results from HOPE-2 Open-Label Extension Study of CAP-1002

Home
/
News & Events
/
News
/
Clinical Trials

Capricor Therapeutics: Positive 18-Month Results from HOPE-2 Open-Label Extension Study of CAP-1002

Capricor Therapeutics Logo

Capricor Therapeutics has shared positive 18-month results from its ongoing HOPE-2 open label extension (OLE) study of CAP-1002 in patients with later-stage Duchenne muscular dystrophy.

Continue reading

REGENXBIO: Phase I/II AFFINITY DUCHENNE™ trial of RGX-202 

Regenx Bio Logo

REGENXBIO has initiated Phase I/II of AFFINITY DUCHENNE™, a gene therapy clinical trial of RGX-202 in the United States.

Continue reading

PepGen: Duchenne Community Newsletter

PepGen Logo

PepGen has provided an end of year update for the Duchenne muscular dystrophy community. Please see their newsletter from Q4 2022.

Continue reading

Santhera and ReveraGen: FDA Acceptance of New Drug Application

Santhera & ReveraGen Logo

Santhera Pharmaceuticals and ReveraGen BioPharma, Inc have announced that the U.S. Food and Drug Administration (FDA) has
accepted the new drug application (NDA) for vamorolone for the treatment of Duchenne muscular
dystrophy.

Continue reading

Sarepta Therapeutics: Submits Biologics License Application for SRP-9001

Sarepta Therapeutics Logo

Sarepta Therapeutics has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the accelerated approval of SRP-9001, an investigational gene therapy for Duchenne muscular dystrophy.

Continue reading

Defeat Duchenne Canada: Sponsored Canadian Clinical Trial Reaches New Milestone

Santhera & ReveraGen Logo

Defeat Duchenne Canada is delighted to announce that the sponsored Canadian clinical trial of vamorolone has reached a key milestone (trial midpoint) of opening higher dose treatment groups to new enrollment.

Continue reading

PepGen: Positive Data from Phase 1 Trial of PGN-EDO51

PepGen Logo

PepGen has announced the results from their completed Phase 1 healthy normal volunteer (HNV) trial of PGN-EDO51, the company’s lead exon skipping product for Duchenne muscular dystrophy.

Continue reading

Roche: Duchenne Research Interview Request

Roche Logo

Roche is now recruiting caregivers and patients who are able to offer their perspectives on completing the North Star Ambulatory Assessment (NSAA) or Performance of Upper Limb (PUL) as part of a new research study.

Continue reading

Edgewise Therapeutics: Positive 4-Month Interim Results from ARCH (EDG-5506)

Edgewise Therapeutics Logo

Edgewise Therapeutics has announced positive 4-month interim results from the ARCH open label study of EDG-5506 in adults with Becker muscular dystrophy (BMD).

Continue reading

Edgewise Therapeutics: FDA Authorization for Phase 2 Clinical Trial of EDG-5506

Edgewise Therapeutics Logo

The U.S. Food and Drug Administration (FDA) has authorized a clinical trial of EDG-5506, an investigational orally administered small molecule myosin modulator designed to protect injury-susceptible fast skeletal muscle fibers in Duchenne and Becker muscular dystrophy.

Continue reading
  • 1
  • 2
  • 3
  • ...
  • 6
  • Next

Sign up to receive our e-news

Get the latest news on Duchenne research, events, support & education, and ways you can help to defeat Duchenne.

All fields are mandatory.

Defeat Duchenne Canada
  • For Researchers
  • For Healthcare Professionals
  • Contact Us
  • Annual Reports
  • FR
×
  • For Researchers
  • For Healthcare Professionals
  • Contact Us
  • Annual Reports
  • FR

Mailing Address
PO Box 51, Station B
London, ON N6A 4V3

+1-519-645-8855

info@defeatduchenne.ca

Donate Now
The Jesse Davidson Foundation
Charitable Number: 89509-7756-RR0001
Facebook-f Twitter Instagram Youtube Linkedin

© 2023 Defeat Duchenne Canada. All rights reserved.

  • Privacy Policy